Web Date: January 29, 2016
Massachusetts Warns Gilead About Hepatitis Drug Prices
Gilead Sciences has received a letter of warning from the attorney general of Massachusetts saying that levying high prices for its new hepatitis C virus (HCV) drugs may constitute an unfair trade practice in violation of Massachusetts law and that the state may pursue legal action if the company does not lower the prices.
Noting that the drugs, Sovaldi and Harvoni, costing $84,000 and $94,500, respectively, per course of treatment, offer a cure to patients, . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society